HIV-1 V3 envelope deep sequencing for clinical plasma specimens failing in phenotypic tropism assays.
BACKGROUND
HIV-1 infected patients for whom standard gp160 phenotypic tropism testing failed are currently excluded from co-receptor antagonist treatment. To provide patients with maximal treatment options, massively parallel sequencing of the envelope V3 domain, in combination with tropism prediction tools, was evaluated as an alternative tropism determination strategy. Plasma samples from twelve HIV-1 infected individuals with failing phenotyping results were available. The samples were submitted to massive parallel sequencing and to confirmatory recombinant phenotyping using a fraction of the gp120 domain.


RESULTS
A cut-off for sequence reads interpretation of 5 to10 times the sequencing error rate (0.2%) was implemented. On average, each sample contained 7 different V3 haplotypes. V3 haplotypes were submitted to tropism prediction algorithms, and 4/14 samples returned with presence of a dual/mixed (D/M) tropic virus, respectively at 3%, 10%, 11%, and 95% of the viral quasispecies. V3 tropism prediction was confirmed by gp120 phenotyping, except for two out of 4 D/M predicted viruses (with 3 and 95%) which were phenotypically R5-tropic. In the first case, the result was discordant due to the limit of detection for the phenotyping technology, while in the latter case the prediction algorithms were not computing the viral tropism correctly.


CONCLUSIONS
Although only demonstrated on a limited set of samples, the potential of the combined use of "deep sequencing + prediction algorithms" in cases where routine gp160 phenotype testing cannot be employed was illustrated. While good concordance was observed between gp120 phenotyping and prediction of R5-tropic virus, the results suggest that accurate prediction of X4-tropic virus would require further algorithm development.
Vandenbroucke
Ina
I
Tibotec-Virco Virology BVBA, Mechelen, Belgium. ivanden3@its.jnj.com.
Van Marck
Herwig
H
Mostmans
Wendy
W
Van Eygen
Veerle
V
Rondelez
Evelien
E
Thys
Kim
K
Van Baelen
Kurt
K
Fransen
Katrien
K
Vaira
Dolores
D
Kabeya
Kabamba
K
De Wit
Stephane
S
Florence
Eric
E
Moutschen
Michel
M
Vandekerckhove
Linos
L
Verhofstede
Chris
C
Stuyver
Lieven J
LJ
Open Virol J. 2008;2:8-14
19440459
AIDS. 2006 Jun 26;20(10):1359-67
16791010
J Virol Methods. 2007 Dec;146(1-2):61-73
17640743
Annu Rev Immunol. 1999;17:657-700
10358771
AIDS Rev. 2003 Apr-Jun;5(2):104-12
12876899
Virology. 2001 Sep 15;288(1):51-62
11543657
Appl Environ Microbiol. 1998 Oct;64(10):3724-30
9758791
Eur J Med Res. 2007 Oct 15;12(9):473-82
17933729
J Virol. 2003 Dec;77(24):13376-88
14645592
PLoS Comput Biol. 2007 Mar 30;3(3):e58
17397254
J Virol. 2002 Sep;76(17):8953-7
12163614
Antivir Ther. 2007;12(7):1097-106
18018768
Nucleic Acids Res. 2007;35(19):e130
17932070